×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Vouchers
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Moneycontrol mutual fund summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Advair
Advair
Cipla: M&A positioning, new US regime are key wild cards
US FDA plant observations at Cipla cause 6-month delay in product launches: CEO
Cipla: Sailing well on the US pharma business front
Cipla: Sharp improvement in margins not likely to sustain
Cipla: Watch out for respiratory and Peptide pipelines
Cipla: Targets for US complex generics on track
Cipla: Focus shifts to FY23 launches
Cipla: M&A opportunity could be near-term trigger
Cipla — Large part of COVID opportunity has played out
Prospects for US business and leadership in respiratory therapies make Cipla attractive
Cipla: Respiratory pipeline adds oxygen, accumulate
When Rakesh Jhunjhunwala grilled Lupin top brass after muted Q4 results
Cipla down 2% on Nomura downgrade, valuations expensive
How generic asthma drug could 'change the face of Cipla'
Inhaler launch in EU to add $55mn to Cipla FY15 rev: Nomura
Cipla at new high, up 8%; respiratory drug launch in UK key
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio